Moderna's New COVID-19 Vaccine Ready for Human Trials; Stock Up 15%
Moderna (NASDAQ: MRNA) announced on Monday afternoon that the company's experimental mRNA COVID-19 vaccine, known as mRNA-1273, is ready for human testing. The initial batch of the vaccine has already been shipped to U.S. government researchers from the National Institute of Allergy and Infectious Diseases (NIAID).
The biotech company expects that the first clinical trials will begin near late April, with around 25 healthy volunteers participating in these tests. Initial clinical results could be available sometime in July or August.
Image source: Getty Images.
Source Fool.com